Illumina, Inc. (NASDAQ:ILMN) Receives $188.40 Consensus Target Price from Brokerages

Illumina, Inc. (NASDAQ:ILMN) has been assigned an average rating of “Hold” from the seventeen analysts that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, six have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $188.40.

ILMN has been the topic of a number of recent analyst reports. Guggenheim lifted their price target on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Evercore restated an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. Canaccord Genuity Group lifted their target price on Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a research note on Monday, August 3rd. Leerink Partners boosted their price target on shares of Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a report on Friday, July 17th. Finally, Citigroup increased their price target on shares of Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research report on Monday, August 3rd.

Insider Activity at Illumina

In related news, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $200.00, for a total value of $123,000.00. Following the sale, the insider directly owned 20,338 shares in the company, valued at approximately $4,067,600. The trade was a 2.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $150.10, for a total transaction of $225,150.00. Following the completion of the sale, the chief accounting officer directly owned 14,946 shares in the company, valued at approximately $2,243,394.60. This trade represents a 9.12% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,416,384 shares of company stock worth $256,164,151 in the last three months. Corporate insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Illumina

Several hedge funds and other institutional investors have recently modified their holdings of ILMN. BlackRock Inc. bought a new position in shares of Illumina in the 2nd quarter worth $3,374,423,000. Plato Investment Management Ltd bought a new stake in shares of Illumina during the 2nd quarter worth $948,000. Impact Partnership Wealth LLC grew its position in Illumina by 235.8% in the first quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company’s stock worth $1,366,000 after acquiring an additional 7,780 shares in the last quarter. Edmond DE Rothschild Holding S.A. purchased a new position in Illumina in the second quarter worth $129,792,000. Finally, Insight Wealth Strategies LLC bought a new position in Illumina in the second quarter valued at $6,062,000. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Up 4.0%

ILMN opened at $213.24 on Tuesday. Illumina has a fifty-two week low of $88.00 and a fifty-two week high of $220.32. The firm has a market capitalization of $32.20 billion, a P/E ratio of 39.78, a PEG ratio of 2.89 and a beta of 1.45. The company’s 50-day moving average is $186.84 and its 200 day moving average is $151.97. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same quarter last year, the business posted $1.19 EPS. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts expect that Illumina will post 5.36 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.